Add time:08/20/2019         Source:sciencedirect.com

A clinical study of a long-acting oral steroid formulation, containing 2.0 mg quinestrol and 2.5 mg quingestanol acetate, was undertaken during a 31-month period. A total of 212 women were enrolled in the study and 2,781 women-months experience was accumulated. Life-table analysis of event rates at the end of 1 year revealed the event rates for discontinuation to be 7.3 for pregnancy, 11.2 for abnormal bleeding and 17.3 for other medical reasons. The cumulative continuation rate at the end of 1 year was only 46.9, indicating this method was not well accepted in this population group.

We also recommend Trading Suppliers and Manufacturers of Quingestanol (cas 10592-65-1). Pls Click Website Link as below: cas 10592-65-1 suppliers